TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02011191

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biotin Supplementation
Description: 10,000 micrograms biotin supplement daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Identical sugar pill, identical bottle as the biotin supplementation group
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT02305693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT02305693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Study: NCT03222349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
Study: NCT03555266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2 Bridge
Description: NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSS-2 BRIDGE
Description: NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
Study: NCT01744288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Oral single loading dose 180ng

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Oral single loading dose 180ng

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral single loading dose 600mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral single loading dose 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion
Study: NCT02582957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sigh breaths
Description: Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
Study: NCT03675880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
Study: NCT03704870

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chest Xray
Description: Daily chest xray

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No daily chest xray
Description: Chest xray will be done post chest tube removal only
Study: NCT03317769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Training on computerized exercises that targets social cognition for 2 hours per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Training on computerized, casual video games for 2 hours per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized social skills training
Description: Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured support group sessions
Description: Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
Study: NCT01392820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, Oral, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, twice daily
Study: NCT03369145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
Study: NCT01243736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Prep
Description: combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope.
Study: NCT01500356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: Weight loss intervention that focuses on reducing energy intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus Moderate Exercise
Description: Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus High Exercise
Description: Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
Study: NCT04536883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microscopy confocal
Description: At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:
Study: NCT03686566

Intervention type: DRUG
Intervention: 13C-glucose
Description: Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes

Intervention type: OTHER
Intervention: No glucose infusion
Description: Only includes standard pre-operation nursing care
Study: NCT00699907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide
Description: Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
Study: NCT03796767

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo salvage oligometastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo salvage oligometastasectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin
Study: NCT00703664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin
Study: NCT03572556

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: * 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: * 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers.

Intervention type: OTHER
Intervention: Epistaxis charts
Description: Three monthly epistaxis charts to be completed
Study: NCT04302532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: antioxidant used to decrease oxidative stress and improve fertility prospects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: ovulation induction drug
Study: NCT00868686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar aluminum splint
Description: Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal aluminum splint
Description: Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom thermoplastic
Description: Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
Study: NCT01181414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrio ventricular junction ablation with radio-frequency
Description: Atrioventricular junction ablation by using radiofrequency energy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker/digoxine/amiodarone
Description: Ventricular rate control by using drug treatment.
Study: NCT04663178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Salt Water Foot Bath
Description: A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
Study: NCT00523991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: Oral inhalation once daily of 18mcg tiotropium via handihaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation once daily of placebo matching tiotropium via handihaler
Study: NCT00009971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Study: NCT01142726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, oral, 2.5 mg, once weekly, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, oral, 2.5 mg, once weekly, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept placebo
Description: Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate placebo
Description: Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Study: NCT03433170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus graft
Description: Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST-Gracilis graft
Description: Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study: NCT00005059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01175798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 50,000 IU PO weekly x 6 weeks
Study: NCT04600895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01681550

Intervention type: DRUG
Group type: OTHER
Intervention: Incretin-based therapy
Study: NCT03431987

Intervention type: DRUG
Intervention: One day with a dose of placebo cannabis paired with alcohol
Description: Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%

Intervention type: DRUG
Intervention: One day with a dose of active THC cannabis paired with alcohol
Description: Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
Study: NCT01543087

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: Blood sample collection at different time points

Intervention type: DRUG
Group type: OTHER
Intervention: bivalent rLP2086
Description: A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
Study: NCT01650090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Lipid Cisplatin (ILC)
Description: ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
Study: NCT01290965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet given once or three times daily for 15 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: oral capsule
Study: NCT01265771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated 24 hours ECG Holter monitoring
Description: Repeated 24 hours ECG Holter monitoring
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's choice of platinum agent
Description: Investigator's choice of platinum agent: carboplatin or cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's choice of platinum agent
Description: Investigator's choice of platinum agent: carboplatin or cisplatin
Study: NCT00637949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lumiracoxib
Description: 400 mg once daily, oral over 6 weeks
Study: NCT00613457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Study: NCT00637949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rofecoxib
Description: 25 mg, oral, daily over 6 weeks
Study: NCT02766582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV every 21 days at 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion (80mg/m2) every 7 days for 6 cycles
Study: NCT03142685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bowel Ultrasound
Description: Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
Study: NCT04504851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: 10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide 25mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 25mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol 15mg/kg
Study: NCT06771557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 656 Online Platform
Description: The 656 Platform provides valuable information regarding three common ailments among the elderly, namely stroke, dementia, and fall-related fractures. Serving as an online platform, the 656 Platform incorporates a Chatbot feature that facilitates connections between local caregivers, social workers, and community members to various services. Serving as an online platform, the 656 Platform incorporates an AI Chatbot and a Live Chat feature that facilitates connections between local caregivers, social workers, and community members to various services. Apart from this, the 656 Platform offers several features that enhance its functionality and user experience, including problem-based elderly resource database, interim care solutions, exchange forum, data analytics and research, and professional knowledge and resources.